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Carbon monoxide (CO) has always been recognised as a toxic gas, due to its higher affinity for haemoglobin than oxygen.
However, biological studies have revealed an intriguing role for CO as an endogenous signalling molecule, a gasotransmitter. CO is
demonstrated to exert many cellular activities including anti-inflammatory, antiapoptotic, and antiproliferative activities. In animal
studies, CO gas administration can prevent tissues from hypoxia or ischemic-reperfusion injury. As a result, there are a plethora
of reports dealing with the biological applications of CO and CO-releasing molecules (CORMs) in inflammatory and vascular
diseases. CORMs have already been tested as a therapeutic agent in clinical trials. More recently, an increased interest has been
drawn to CO’s potential use as an anticancer agent. In this review, we will aim to give an overview of the research focused on the
role of CO andCORMs in different types of cancer and expand to the recent development of the next generation CORMs for clinical
application in cancer treatment.
1. Introduction
Since 1949 when carbonmonoxide (CO) was firstly identified
as a natural metabolite in the exhaled air of healthy humans,
it took a long time to be recognised as a molecular mediator.
CO has been classified with other biologically active diatomic
molecules, such as nitrogen oxide (NO) and hydrogen sul-
phide (H
2
S), as a gasotransmitter [1]. Naturally, CO is an
inert gas, colourless, odourless, tasteless, and nonirritating.
For decades, CO had the reputation of a “silent killer” owing
to its more than 220 times stronger affinity for iron atoms
in haemoglobin than oxygen, with the subsequent formation
of carboxyhaemoglobin (HbCO). This binding significantly
reduces the oxygen-carrying capacity of haemoglobin, con-
sequently leading to tissue hypoxia and CO poisoning in
humans [2]. Despite known as an environmental pollutant,
CO is constantly produced in healthy humans endogenously
[3].The formation of endogenousCO ismainly carried out by
a family of enzymes known as haemoxygenases (HOs), found
as three isoforms: HO-1, HO-2, and HO-3 [4]. HO-1 and
HO-2 catalyse the oxidative conversion of heme to ferrous
iron, CO, and biliverdin, which is subsequently reduced to
bilirubin by biliverdin reductase [5] (Figure 1). The function
of HO-3 remains unclear, but it is viewed as a pseudogene
derived from HO-2 transcripts [6]. HO-1, mainly found
in spleen and liver, but also in vascular endothelial cells
and smooth muscle tissues, is the only inducible isoform,
increased as a result of several stimuli provoked by cellular
stress. HO-2 and HO-3 are ubiquitously expressed in the
brain, liver, and testes, with HO-2 being responsible for
neurotransmission and regulation of vascular tone [2, 4, 5].
The endogenous actions of CO derive from its role as a
physiological signalling molecule and affect many systems,
such as the neuronal, cardiovascular, immune, respiratory,
reproductive, and gastrointestinal systems [3]. CO exerts
antiapoptotic, anti-inflammatory, and antioxidant effects,
being able to maintain cell and tissue homoeostasis. It also
acts as an antiproliferative and vasodilator agent and may
be involved in tissue regeneration and strengthen the innate
immune system [1, 3]. There is much evidence supporting
the beneficial effects of CO in a vast array of diseases, such
as cardiovascular disorders, sepsis and shock, cancer, acute
and chronic rejection after organ transplantation, kidney and
liver dysfunctions, haematological diseases, hypertension,
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Figure 1: Oxidative conversion of heme.This figure depicts a summary of the formation of endogenousCO, carried out by a family of enzymes
known as haem oxygenases (HOs), found as three isoforms: HO-1, HO-2, and HO-3.
inflammation, and neurodegeneration [2–4, 7]. All these
conditions have been linked to abnormalities in the function
of HOs and endogenous COmetabolism. However, the great
number of diseases affected and potentially benefited by
CO reflects the complexity of the CO-dependent signalling
networks, which produce different responses according to the
stimulus and type of tissue considered [2].
Although CO is suggested to be involved in many patho-
logical conditions, the relevant research is only at an early
stage, with many diseases yet to be explored towards their
response to this interesting diatomicmolecule. Since only few
studies are focusing on the role of CO, along with biliverdin,
bilirubin, iron, and ferritin, in carcinogenesis [8], this review
aims to elucidate the role of this gasotransmitter in the
form of CORMs, in tumorigenesis, along with angiogenesis
and metastatic progression. We also want to highlight the
development of CORMs, commonly used as alternatives to
CO gas administration, as a type of “prodrug.”
2. Carbon Monoxide-Releasing
Molecules (CORMs)
Although CO gas exerts a broad range of biological effects
with many potential therapeutic applications, the lethality
derived from CO effects on oxygen transport prevents the
systemic CO application. Other practical issues include the
global diffusion of CO, incapable of targeting specific cells
or tissues, as well as the challenge of effective dose control.
Therefore, a group of transition metal carbonyls or bora-
nocarbonates, known as CO-releasing molecules (CORMs),
which can release CO upon transformation becomes the
best alternative to gas administration [2–5, 9, 10]. Since high
concentrations ofCOare proven to be cytotoxic via inhibition
of the mitochondrial respiratory system [11, 12], CORMs
offer a possible strategy for a local release of high amounts
of CO for specific cytotoxicity only to the tumour region
[1].
CORMs were first introduced as industrial catalysts and
for purification purposes. They usually contain a transi-
tion metal core, such as manganese, ruthenium, or iron,
surrounded by some carbonyl groups (CO) as coordinated
ligands [5]. Both Schatzschneider and Zobi recently reviewed
the potential trigger mechanisms for CO release from these
compounds and categorized them into three groups [4,
13, 14]: (1) first group that releases CO due to ligand
exchange reactions with the medium, (2) second group that
needs a proper internal or external stimulus to induce the
release, and (3) third group that explores differences in
cellular microenvironments, such as enzyme expression or
pH, to be used as alternative trigger mechanisms. These
approaches could finally provide novel molecules with the
ability of delivering tissue-targeted, internally triggered, and
dose-controlled CO. Indeed, CORMs have shown a variety
of activities, such as vasodilatory, anti-inflammatory, anti-
apoptotic, anti-ischemic, and cardioprotective activities, and
have also been proven to regulate mitochondrial respiration
[3].
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Figure 2: Structures of classic and novel CORMs.
Since 2008, a particular group of light-activated CORMs
(also called photo-CORMs) has received most of the scien-
tific interest. Under specific conditions, photoexcitation of
the metal-carbonyl bond can lead to the dissociative loss
of CO [5]. Photo-CORMs have been developed to meet
certain criteria of all chemical compounds intended to be
used as pharmaceutical drugs, which other CORMs failed
to address [15]. Apart from a favourable pharmacokinetic
behaviour concerning the properties of absorption, distribu-
tion, metabolism, and excretion (ADME), CORMs should
also possess other characteristics, such as water solubility,
biocompatibility, stability in aqueous aerobic media and
air, low toxicity and quick detoxification of the M(CO)
𝑥
fragment, and traceable nontoxic metabolites [1, 4]. Once the
bioavailability and optimal distribution of the photo-CORM
are achieved, photochemical excitation of the metal-carbonyl
bond could allow for controlling the timing, dosage, and
location of the CO released. Until now, the primary challenge
in the designing of new photo-CORMs is the selection of
the ideal radiation wavelength at which they are activated.
Currently, in vivo applications of the phototriggered CORMs
may be limited to the sites of the body surface or the sites
of the body closer to the surface [1, 4]. There are several
reviews published on the matter of photo-CORMs, a quite
comprehensive one being by Rimmer et al. [15].
A very interesting new generation of transitionmetal free
CORMs based on boron-dipyrromethene (BODIPY) chro-
mophores (named COR-BDPs) were synthesised by Palao et
al. [16]. These molecules are activatable by visible-to-near-
infrared (up to 730 nm) light. These wavelengths are highly
desired, since they display a better penetration into biological
tissues. Three structures of mesocarboxy BODIPY (COR-
BDP) derivatives, 3a, b, and c, were reported (Figure 2(A)).
Neither 3a and b nor their photoproducts displayed toxicity
in in vitro experiments on hepatoblastoma HepG2 and
neuroblastoma SH-SY5Y cell lines up to concentrations of
100 𝜇M. However, after CO release studies, the researchers
found that 3c, unlike 3a and b, undergoes a photoreaction
that does not lead to CO production. The main advantage
of these COR-BDPs is that the BODIPY scaffold allows for
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fine-tuning of the physicochemical properties of the final
molecules, such as optical properties or aqueous solubility.
Moreover, simple structural modifications are feasible; there-
fore a rapid development of improved CORM molecules
could be achieved. The therapeutic potential of COR-BDPs
remains to be investigated in further studies [16].
As previously mentioned, CORMs regulate intracellular
pathways, which play significant roles in inflammation, apop-
tosis, and cellular proliferation [7]. The preclinical efficacy
and the structures of a broad range of early and newly
synthesised CORMs have been recently reviewed [1, 3, 4,
7, 17]. It is pretty evident that numerous diseases can be
affected by these compounds, indicating the complexity of
CO-signalling networks. Compared to many reports with
the biological applications of CORMs in inflammatory and
vascular diseases, microbial infections, and organ transplan-
tations [2, 3, 5, 7, 10], little interest has been drawn to the
potential use of CO and CORMs as anticancer agents. In this
review, we aim to summarise the research that has been done
so far to elucidate the effects of CO and CORMs on different
subtypes of cancer.
3. CORMs and Cancer Therapy
The potential application of CO and CORMs in cancer
therapy is still controversial [1, 18].Themolecular targets and
specific signalling pathways affected by CO remain unclear,
which often leads to contradicting reports [19–21]. The most
possible scenario is that CO can stimulate opposite effects
in various biological systems. CORMs have been studied for
their influence on cell proliferation, apoptosis, and angio-
genesis, primary processes involved in cancer initiation and
progression, and the conclusion until now is that this effect
is variable and seems to be cell-type specific [18, 22]. So, the
main purpose of this review is to gather the experimental data
available to date on the potential effects of CO and CORMs
on various cancer subtypes. In this review, organometallic
carbonyl complexes which are incapable of releasing CO are
excluded, since the point of interest is the effect of CO gas or
CORMs on cancer.
3.1. Breast Cancer. Being one of the most common sub-
types of cancer, breast cancer was immediately considered a
potential target disease for CO and CORMs. In that scope,
Lee et al. [23] found that CO, as a byproduct of HO-1,
could attenuate heat shock protein 90 (HSP90) activity and
reduce the expression of its client proteins, which participate
in the six hallmarks of cancer. The novelty of this study
lied upon the inhibitory mechanism elucidation, since they
demonstrated that treatment with CORM-2 up to 100𝜇M
and for 24 h (Figure 2(B)), as a source of CO, increased
wild type (WT) p53 expression in MCF-7 breast cancer cells,
while it reduced mutant p53 levels in MDA-MB-231 breast
cancer cells. Mutant p53 is an oncoprotein addicted to HSP90
and, together with other HSP90 client proteins, including
cyclinD1 and Akt, that were also shown to be reduced
by CORM-2 indicated a CO-induced downregulation of
HSP90 activity. This result revealed a potential therapeutic
advantage of CORM-2, since targeting HSP90 may deal
with multiple molecules at the same time and it seems
that CO plays an important role in the modulation of this
chaperone [23]. Carrington et al. [24] synthesised two man-
ganese carbonyl complexes, namely, fac-[MnBr(azpy)(CO)
3
]
(1) and fac-[Mn(azpy)(CO)
3
(PPh
3
)](ClO
4
) (2), which were
characterized as photo-CORMs. The two CORMs released
CO upon irradiation with low power visible light. The anti-
cancer potential of the former was evaluated via MTT assay
on MDA-MB-231 breast cancer cells, under the control of
visible light. Upon irradiation, a dose-dependent eradication
of the cancer cells was observed, with a concentration of
75 𝜇M killing nearly 40% of the colony. Therefore, this
complex offered anti-breast cancer activity through unique
light-controlled CO delivery [24]. The same group [25]
also applied a novel technique for drug delivery, utiliz-
ing Al-MCM-41 mesoporous silica nanoparticles (MSNs)
loaded with a newly synthesised photo-CORM, namely,
fac-[Re(CO)
3
(pbt)(PPh
3
)](CF
3
SO
3
), (ReCO), for the selec-
tive delivery of the photo-CORM to breast cancer cells.
The endocytosis of the [Re-CO]@Al-MCM-41 MSNs within
MDA-MB-231 breast cancer cells provides the opportunity
for trackable CO delivery, due to a “turn-off” effect of
a systematic decrease in luminescence intensity upon UV
irradiation. Moreover, they tested the anticancer activity of
the endocytosed particles after light-induced CO release on
MDA-MB-231 cells via MTT assay. The results indicated an
80% eradication of the cancer cells at a concentration of
0.25mg/mL of the nanoparticles, a much stronger effect than
that after the application of the photo-CORM alone, due
to the extravasation of nanosized particles occurring in a
tumour-selective manner [25]. In a later study, Carrington et
al. [26] designed a fluorescent manganese carbonyl complex,
namely, fac-[MnBr(CO)
3
(pbt)], whichwas sensitive to visible
light and displayed an increase in fluorescence upon CO
release as a “turn-on” photo-CORM. This complex showed
a dose-dependent inhibition of MDA-MB-231 breast cancer
cells, by reducing their viability approximately 50% at the
highest concentration of 100 𝜇M, under visible light illumina-
tion.The results suggested that thismanganese photo-CORM
was able to deliver CO to biological targets upon irradiation
with visible light, provoke CO-induced apoptosis in human
breast cancer cells, and offer the ability to track CO delivery
within the cells, because of the highly fluorescent pbt included
in the complex [26]. Finally, U¨stu¨n et al. [27] synthesised
fac–manganese (I) tricarbonyl bipyridine complexes with
imidazole and benzimidazole substituents (Figure 2(C)),
which were shown to release CO upon UV light irradiation.
The anticancer potential of these complexes was investigated
against a human invasive ductal breast carcinoma (MCF-7)
cell line and all of them displayed promising IC
50
values of
low micromolecular range. However, since the aim of the
study was to inhibit breast cancer cell proliferation upon
UV irradiation due to the release of CO from the designed
compounds, the same in vitro experiment was repeated with
a 10-minute irradiation at 365 nm and the different IC
50
s
were reported. It seems that compounds 1, 3, and 5 exert
cytotoxic effect on MCF-7 cells, and UV irradiation does not
enhance cytotoxicity of these compounds. On the contrary,
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compounds 2 and 4 express a UV-dependent cytotoxicity,
following the principles of photo-CORMs design. Therefore,
compounds 2 and 4 may provide photodynamic agents for
anticancer therapy with controlled CO release profiles [27].
3.2. Prostate Cancer. Prostate cancer is the most common
type of cancer in males. Jackson et al. [28] described the
synthesis of a new photo-CORM [FeII(CO)(N
4
Py)](ClO
4
)
2
(Figure 2(D)) that released CO after UV light irradiation,
which was tested for its anticancer effect on PC-3 prostate
cancer cells.Their data clearly demonstrated a concentration-
dependent eradication of the cancer cells, with the greatest
effect at 10 𝜇M. Also, the authors found that this complex
possesses a suitable ligand structure for peptide attachment
[28]. In addition, Pierri et al. [29] generated a novel photo-
CORM, a water-soluble rhenium complex, that is, fac-
[ReI(bpy)(CO)
3
(thp)]+. This complex, as well as its photo-
product, did not show significant toxicity against human
prostatic carcinoma cells PPC-1 in the dark up to 100 𝜇M.
However, the experiments demonstrated a significant aggre-
gation in the cytoplasm, but not within the nucleus [29].
Further experiments are needed though to evaluate the
possible anticancer activities of fac-[ReI(bpy)(CO)
3
(thp)]+.
3.3. Colon Cancer. Niesel et al. [30] reported a novel man-
ganese complex, namely, [Mn(CO)
3
(tpm)]PF
6
(Figure 3(A)),
that could be activated by UV light and used as a potential
photo-dynamic-therapy (PDT) agent. According to cellular
uptake studies, this complex was suggested to enter the cells
by passive diffusion rather than active transport and thus
may be useful for cellular delivery of CO. The differential
cytotoxicity of the complex with or without irradiation was
tested on HT29 colon cancer cells via the crystal violet assay.
Upon irradiation, the complex inhibited cell growth com-
parable to the well-known anticancer agent 5-fluorouracil,
reducing cell biomass nearly 30% compared to the control
at a concentration of 100 𝜇M. Therefore, this complex may
serve as a PDT agent against colon cancer [30]. Bru¨ckmann
et al. [31] synthesised a series of complexes exploring the
idea of linking photo-CORMs to HPMA-based copolymers,
generating functionalized copolymers (Figure 3(B)). The
cytotoxicity of these complexes was tested on Hct116 human
colon carcinoma cells and compared to that of CORM-2.
Only two of these compounds showed toxicity, with IC
50
values close to 50 𝜇g/mL for both. However the researchers
concluded that it was not a direct result of CO release, because
the toxicities of the two complexes remained the samewith or
without irradiation.This study demonstrated the feasibility of
developing ligand functionalized polymers as carrier systems
for Mn(CO)
3
-based CORMs for the passive delivery of these
CORMs to tumour tissues or other sites [31].
3.4. Cervical Cancer. The manganese complex fac-
[MnBr(azpy)(CO)
3
], previously mentioned in the breast
cancer section, was also tested for inhibitory effects on a
cervical cancer cell line, that is, HeLa cells [24].This complex
exhibited similar anticancer effects on the cervical cells as
those against the breast cancer cell line upon irradiation
with visible light. The complex caused certain morphological
changes to the cervical cancer cells, indicating an apoptotic
cell state, suggesting a potential use as an anticancer agent for
breast or cervical cancers, with the advantage of a favourable
light-controlled CO release [24]. Hu and colleagues [32]
designed a series of N-substituted molybdenum, tungsten,
and manganese carbonyl complexes containing various
heterocycles (Figure 3(C)) which were tested for cytotoxicity
on HeLa cells. Apart from complex 4, the rest of series
complexes exert modest inhibitory effects on HeLa cells,
without significant cytotoxicity. Among them, complex
3 was the most potent, with an IC
50
of 37.22𝜇M [32].
Interesting are also the relatively slow CO-releasing cobalt-
containing CORMs (Figure 3(D)) designed by Gong et
al. [33]. Appropriate MTT assays showed that the slow
CO-releasing CORMs could inhibit the proliferation of
HeLa cells with IC
50
s less than 120 𝜇M, reflecting their
potential anticancer activity.The data of animal experiments,
further, showed low LD
50
values via the oral acute toxic
class method (ATC), in the range of 5000mg/kg. The
mechanism of action was further studied, revealing a
concentration-dependent apoptotic effect of complexes 1
and 6, mainly in the later stage. Finally, the authors proved
that these complexes could block cell cycle in the G2/M
phase, inhibiting division and proliferation, and increasing
intracellular reactive oxygen species (ROS) concentration,
possibly through CO and cobalt ions released after CO loss.
Hence, they hypothesised that the antiproliferative activity
of the synthesised compounds resulted from the binding
of CO to proteins of the mitochondrial electron transfer
chain leading to an intracellular ROS level increase, as well
as the release of cobalt species that can bind to endogenous
substrates interrupting cell cycle and provoking apoptosis
[33].
3.5. Pancreatic Cancer. Vı´tek et al. [34] first indicated that
CO, in the form of CORM-2 or CO gas, exerted a potential
antiproliferative effect on a panel of human pancreatic cancer
cell lines, in a dose-dependent manner. CO inhibited the
proliferation of the PaTu-8902 cells and induced apoptosis in
the CAPAN-2 pancreatic cancer cells at a concentration of
50 𝜇M. CORM-2 treatment led to an increase in the survival
rate of in vivo pancreatic cancer models with a significant
decrease in the tumour volumes at 35mg/kg/day. CORM-2
was also able to substantially affect de novo angiogenesis via
suppressing Akt phosphorylation, a significant contributor
to cancer neovascularisation. The authors concluded that
exogenously applied CO, either in the form of CORM-2 or as
direct CO gas exposure at 500 ppm, could inhibit pancreatic
tumour growth and tumour neovascularisation and prolong
survival and thus could act as an inhibitor of pancreatic
carcinogenesis [34]. Schwer et al. [35] on the other hand
identified the inhibitory effects of CORM-2 on components
of the translational machinery and global protein synthesis of
pancreatic stellate cells (PSCs). Being a common histopatho-
logical feature in pancreatic cancer, fibrosis has been shown
to be significantly affected by both processes of translation
and protein synthesis. CORM-2 prevented serum-induced
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Figure 3: Structures of novel CORMs.
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eEF2 dephosphorylation, in a time-dependent manner and
inhibited the PI3K-Akt-mTOR signalling pathway in PSCs,
independently of the ERK1/2 signalling pathway, at concen-
trations of up to 100 𝜇M. Moreover, CORM-2 treatment at
the highest concentration used resulted in a 51% reduction in
the protein synthesis of PSCs, which combined with elevated
intracellular calcium and cAMP levels indicated that CORM-
2 could inhibit the translational machinery, regardless of
HO-1 induction.The anti-inflammatory and antiproliferative
effects of CORM-2 could hence be via repressing global
protein synthesis [35].
3.6. Skin Cancer. The antiphotocarcinogenic properties of
CO were established in another study by Allanson and Reeve
[36]. They explored whether CO signalling has an anti-skin
cancer function.Their results suggested that topically applied
CORM-2, in the form of lotions of 250 and 500 𝜇M and
as a source of CO, produced a moderate inhibition of early
tumour appearance, increased the elimination of established
tumours, and inhibited the development of malignant and
locally invasive large tumours. All the effects of CORMs
were dose-dependent, even though not always following the
expected pattern. CORM-2 also appeared to significantly
reduce average tumour multiplicity [36].
3.7. Lung Adenocarcinoma. HO-1 was shown to inhibit lung
adenocarcinoma cell growth via generation of CO [8]. CO gas
treatment, instead of CORMs, could cause a time-dependent
inhibition in the frequency, proliferation, and size of the
tumour nodules in a lung tumour Kras mouse model, if
administered at 250 ppm for 1 h/day. Also, CO gas increased
the levels of mtTFA indicating mitochondrial stress. CO
gas could not enhance the sensitivity of A549Rhoo, the
mitochondria-depleted A549 cells, to doxorubicin, suggest-
ing that CO gas may rapidly enhance mitochondrial activity
of cancer cells, resulting in metabolic exhaustion and cellular
collapse under intense oxidative stress and thus tumour
regression [8]. A549 cells were derived from the lung tumour
Kras mouse model.
3.8. Lymphoma and Acute Myeloid Leukaemia. Loureiro et
al. [37] developed a novel nanocarrier system loaded with
6 𝜇M CORM-2. The system was tested on a lymphoma cell
line (A20 cell line), as well as in vivo in BALB/c mice bearing
subcutaneous A20 lymphoma tumours. To take advantage
of the ability of the nanocarriers to affect the pharmacoki-
netics and drug distribution to different tissues, PEGylated
and folic acid- (FA-) functionalized BSA nanoemulsions
were generated, which could specifically deliver CORM-2
into FA receptor-positive cancer cells. The authors found
that CORM-2 could halt A20 cell proliferation, possibly
via HO-1 signalling, without affecting endogenous reactive
oxygen species (ROS) levels. These nanoemulsions loaded
with CORM-2 also led to a decrease in cell viability in
vitro, measured via MTT assay. In the in vivo experiments,
treatment with these nanoemulsions containing CORM-2
resulted in a 46% reduction in the tumour size, as well
as enhanced survival rates [37]. The study by Schlawe et
al. [38] demonstrated a new class of cytostatic, apoptosis-
inducing agents.The authors generated some iron-containing
nucleoside analogues (Figure 4(A)) and tested them for
their cytotoxic activity against a lymphoma B cell line,
namely, BJAB cells. The cytosine derivatives were the most
potent complexes with IC
50
s of 20–30𝜇M. Iron-containing
nucleosides appeared to be able to induce concentration-
dependent apoptosis, based on the observation of blebbing,
as well as DNA fragmentation after treatment with 20𝜇M.
The antileukemic potency of the new nucleosides was also
evaluated, with one particular complex efficiently inducing
apoptosis in an ex vivo DNA-fragmentation assay involving
primary leukemic lymphoblasts. However, the mechanism
of action needs to be further elucidated but may involve
CO release as well [38]. Finally, a new series of organic
photo-CORMs based on unsaturated cyclic 𝛼-diketones (Fig-
ure 4(B)), encapsulated in Pluronic F127 micelles at 407𝜇M,
were also reported by Peng et al. [39]. The novel organic
CORMs could initiate a photoreaction triggered by visible
light instead of UV light, required by most organometallic
photo-CORMs for CO release. The authors tested these
micelle-encapsulated organic photo-CORMs for effects on
leukemic (KG1) cell proliferation and viability by flow cytom-
etry. Their results showed that the viability of the cells was
not altered by the photo-CORMs or the anthracene based
fluorophore. Also, no photodamage was observed.Therefore,
this study revealed a new approach in the designing and
synthesis of new photo-CORMs, beyond their potential use
as anticancer agents, which can prove well suited for possible
targeted delivery of CO to biological systems [39].
4. Mitochondrial Respiration and
Glucose Biotransformation
Toxic effects of CO are due to its high affinity for the reduced
iron-heme in haemoglobin, crucial for the delivery of oxygen
(O
2
) to tissues. Thus, CO can compete with O
2
for the
binding site of heme on the mitochondrial cytochrome c
oxidase, one of its central targets, and become harmful for
cellular respiration [40]. CO has also been shown to increase
mitochondrial biogenesis and ATP and ROS generation,
which also affects cellular behaviour [4, 7, 8]. For instance,
increased ROS production can lead to the upregulation of
peroxisome proliferator-activated receptor 𝛾 (PPAR𝛾) and
hypoxia-inducible factor 1𝛼 (HIF-1𝛼) [7].
A proof-of-concept study by Lo Iacono et al. [11] sug-
gested that CORM-3 (Figure 4(C)) could prove a novel
regulator of mitochondrial respiration, via the liberated
CO, that could be useful for diseases where mitochondrial
uncoupling and metabolism are targeted as therapeutic
options. Interestingly, low concentrations of CORM-3, 2–
50 𝜇M, stimulated a concentration-dependent increase in
O
2
consumption during state 2 respiration, which could be
blocked by a CO scavenger, whereas a decrease was observed
for state 3 respiration rate. However, higher concentrations
of CORM-3, 50–100𝜇M, were able to reduce state 2 respira-
tion. The iCORM-3 (unable to release CO) could not exert
the same effects, suggesting that the uncoupling effect and
8 Oxidative Medicine and Cellular Longevity
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Figure 4: Structures of first-generation and novel CORMs.
inhibition of mitochondrial respiration caused by CORM-3
aremost likely due to CO rather than the rest of themolecule.
Furthermore, CORM-3 was also shown to accelerate O
2
consumption and inhibit complex IV individually, at the
highest concentration tested (100 𝜇M) [11]. Takano et al. [41]
found that there should be an alternative mechanism for
cellular energetics to maintain ATP in the CO-exposed cells.
The authors examined the impact of CO on cell bioenergetics
and glucose utilization through the fluxome analysis with
liquid chromatography-mass spectrometry (LC-MS/MS), on
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U937 cells. Their results showed that CORM-2 at 100 𝜇M,
as a source of CO, regulated glucose biotransformation and
suppressed glycolysis, results that need further examination
though [41].
5. Effects of CORMs on
Cancer-Related Conditions
5.1. Cardiotoxicity of Doxorubicin. CORMs have also been
considered against other cancer-related pathological condi-
tions, most commonly side effects caused by other anti-
cancer drugs. In that scope, Soni et al. [42] demonstrated
the potential protective properties of CO, in the form of
CORM-2, against the doxorubicin- (DXR-) induced acute
cardiac failure-cardiotoxic effects. The mouse model treated
with CORM-2 (30mg/kg) for a long period before DXR
administration manifested the less impaired heart function
compared to that treatedwithDXRalone at a dose-dependent
manner (3–30mg/kg, i.p.). These cardioprotective effects
were probably derived from the CORM-2-induced reduction
in the serum levels of creatine kinase (CK) and lactate dehy-
drogenase (LDH), leading to further attenuation of oxidative
stress and cardiomyocyte apoptosis. In addition, the study
suggested that CORM-2 protection against cardiotoxicity
may involve the activation of the HO-1 signalling pathway,
by increasingHO-1mRNA expression inDXR-treatedmouse
hearts. Thus CORM-2 should be considered a therapeutic
prevention for DXR-induced cardiotoxicity [42].
5.2. Nephrotoxicity of Cisplatin. A notorious side effect of cis-
platin (CP-a widely used anticancer drug) is nephrotoxicity.
Tayem et al. [43] examined CORM-3 as a potential protective
agent against nephrotoxicity using both in vitro and in
vivo assays. CORM-3 (1–50𝜇M) appeared to ameliorate the
CP-induced nephrotoxicity and renal dysfunction through
protecting both renal tubule epithelial cells (LLC-PK1) and
kidneys against the structural and functional impairment
induced by CP. In vivo administration of CORM-3 (10mg/kg,
i.p.) prevented CP-induced acute renal failure and helped in
preserving kidney morphology and preventing weight loss.
Their study indicated a novel use of CORMs, as sources of
endogenous CO, as alternative agents to prevent CP-induced
nephrotoxicity [43].
5.3. Radiotherapy-Induced Secondary Cancer. From another
point of view, Tong et al. [44] studied the potential employ-
ment of low-concentration CO combined with radiother-
apy, which may lead to protecting normal tissues beyond
the irradiated area against the radiation-induced bystander
effects (RIBE), preventing secondary cancer. By using the
RIBE system, an increase in chromosome aberration in
proliferating bystander Chinese hamster ovary (CHO) cells,
the authors successfully showed that low concentrations
of exogenous CO, delivered by CORM-2 at 14𝜇M, could
effectively inhibit the RIBE-induced cell proliferation and
chromosomal abnormality (MN and NPB) [44].
6. CORMs and Angiogenesis
The effects of CO gas and CORMs on tumour angiogen-
esis are again highly controversial. Different studies report
contradicting results based on the types of tumours studied.
They conclude that these agents have either a pro- or
antiangiogenic effect based on the type of cells involved.
Choi et al. [45] suggested a stimulatory effect of CO
on angiogenesis, mainly mediated by elevated intracellular
ROS levels in endothelial cells. This effect is directly linked
to the inhibitory activity of CO on mitochondrial complex
IV, involved in the respiratory system of these organelles
[1, 45]. The authors also reported that CO could induce
proangiogenic factors, such as VEGF and IL-8, and suppress
antiangiogenic mediators. The same group [46] in another
study reported that CO could induce VEGF expression
through hypoxia-induced factor 𝛼 (HIF-1𝛼) activation and
stabilisation. Similarly, CORM-2 could provoke a paracrine-
style of proangiogenic activity. The media derived from
astrocytes treated with CORM-2 could stimulate human
umbilical vein (HUVEC) cells to proliferate, migrate, and
form tubes, an action that could be inhibited by a VEGF-
neutralizing antibody. CORM-410, a novel oxidant-sensitive
CORM, was reported to promote angiogenesis via CO-
mediated induction of HO-1 and phosphorylation of p38
MAP kinase. In addition, CORM-401 increased VEGF and
IL-8 levels, both highly involved in angiogenesis [47]. Fang
et al. [48] found that CORM-2 could increase tumour blood
flow, thus having a proangiogenic effect on solid tumours.
Other papers reported similar results that CO could induce
VEGF expression or enhance its angiogenic activity [49–51].
In contrast, there are reports suggesting that both HO-1
and CO could have variable functions, based on the different
cellular microenvironments [48, 49, 51, 52]. Some of these
reports described an antiangiogenic effect ofHO-1 andCOon
cancer cells [19, 34, 52]. Ahmad et al. [19] showed thatCORM-
2 (50 𝜇M) could inhibit VEGF-related cell proliferation and
migration via inhibition of VEGF-R2 and protein kinase
B (Akt) phosphorylation in HUVEC cells. In pancreatic
cancer, CO inhibited endothelial proliferation and reduced
microvascular density of xenon cancermodels [34].The study
by Skrzypek et al. [53] indicated that CORM-2 treatment also
led to the inhibition of angiogenic mediators in non-small-
cell lung cancer.Moreover, as previouslymentioned for breast
cancer, CORM-2 was proved to downregulate the HSP90
client protein activity [23] and inhibit the synthesis ofMMP-9
[54].
Loboda et al. [18] have comprehensively discussed the
controversial effects of CO gas or CORMs on angiogenesis.
The authors thoroughly examined both potential types of
effects that may be modulated by heme oxygenase-1 (HO-1)
and CO regarding angiogenesis. First they make the point
that (1) induction of angiogenesis is mainly supported by
an increase in growth factors synthesis and activation, an
inhibition of the differentiation of cancer stem cells, and a
boost in VEGF expression and release and (2) angiogenesis
may be attenuated via a decreased synthesis of angiogenic
mediators, an inhibition on the phosphorylation of key
kinases, and a metabolic switch from glycolysis towards the
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pentose phosphate pathway. In this review as well as all
others, CO is suggested to influence tumour angiogenesis in
opposite ways. It has been reported to increase the synthesis
of growth factors and improve the viability of endothelial cells
and may be linked to cancer initiating cells. CO could also
increase VEGF synthesis and other proangiogenic factors.
However, in other cancers, high HO-1 expression and CO,
often in the form of CORMs, were correlated with impaired
tumour growth. Indeed, as mentioned above antiangiogenic
activities of CO were reported in various studies, as well as
antiproliferative effects and inhibition of xenotransplanted
tumours. CO was also correlated with downregulation of
HSP90 client protein activity and inhibition of the synthesis
of MMP-9. Therefore, it is obvious that the perplexity of the
potential role of HO-1/CO still remains to be elucidated, and
it is urgently needed to further examine how this role is
implicated in tumour development and angiogenesis. Only in
this way could CORMs be considered for more personalised
therapies, potentially as additional therapeutic agents for
cancer patients [18].
7. Designing of New CORMs
So, the question now is, what is next?There is a growing inter-
est in developing novel CO-based therapeutics, and as the
understanding of CO biology increases every day we expect
to see CORMs becoming a new class of therapeutics against
various diseases soon [55]. There have been many obstacles
for CORMs to develop as clinically useful agents, though.
Themain problem is obviously solubility, but researchers have
been able to address this problem successfully. Nevertheless,
there are many other issues to be dealt with, such as stability
in air and water, biocompatibility, how to ensure low or no
toxicity of the metal-fragment left after the release of CO,
and favourable pharmacokinetics [1, 2, 4, 7]. Apart from
the properties of absorption, distribution, metabolism, and
excretion (ADME) required for all drug-like substances, the
most important feature of effective CORMs is to be able to
reach the appropriate disease sites where they can release CO
via a certain trigger or stimulus in the proper amount and
time [1, 2, 10]. Moreover, the half-life of the CORM in the
circulation and the release of CO are crucial for the desired
therapeutic effect.Thedesign of newCORMs should be based
on finding suitable ligands capable of tuning the half-life of
the CO release [2, 4, 13].
The structure of a CORM contains three parts: the
metal core, the ligand (inner) coordination sphere or CORM
sphere, and the drug (outer) sphere. The ligand sphere
determines the kinetics and stoichiometry of the CO release,
given a proper metal core, whereas the drug sphere should
provide the CORM with desired characteristics, such as
favourable ADME and tissue-specific targeting elements [1,
13]. Comprehensive reviews of conceptualising novel CORM
structures are introduced by many researchers [4, 10, 13].The
most important aspects of designing new CORMs include
the number of releasable CO groups, the kinetics of the CO
release, and the trigger mechanisms required for initiation.
The chemical versatility of these compounds is their most
significant advantage over CO gas. The appropriate targeting
ligands conjugated to the metal-carbonyl scaffold allow for
their spatial distribution in the various body fluids and
tissues, even in different cell subpopulations [4, 13].
As for the special class of photo-CORMs, additional
properties are required, such as photoreactivity at specific
wavelengths where the penetration depth is optimal, thatmay
allow for total control of the delivery and activation of these
compounds. This could only be achieved by suitable metal
and coligand combinations [15, 55, 56].
8. Conclusion
Further development of metal-based CORMs is on its way
and we expect to see more advanced and well-targeted
molecules arising in the near future. In this perspective,
it would be even possible to select the proper CORM for
the therapeutic action needed, according to its CO-releasing
profile and pharmacokinetic behaviour. Overall, appropriate
designing and synthesis of novel molecules could prove
invaluable towards amore personalised cancer treatment and
a reduced drug load for cancer patients [4].
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